US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-01 08:52:46 Source:sportViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Confidence of US consumers continues to decline as Americans worry about the future
Next:Using a walker boot for too long may mean you can't ever walk properly without it again
You may also like
- Proof you CAN outrun bad genes with just four lifestyle tweaks
- Shane Bowen has big shoes to fill in replacing Wink Martindale as Giants defensive coordinator
- Internet customers in western North Carolina to benefit from provider's $20M settlement
- Proposed design for a train station in Nanjing is ridiculed by Chinese internet users
- US, Mexico drop bid to host 2027 World Cup
- Chilling 911 audio reveals moment Ohio cops find Uber driver, 61, dying on 81
- Lottery, gambling bill heads to Alabama legislative conference committee for negotiations
- It was one of the most joyous
- Denise Welch confirms she's moved house after knife